Riverbridge Partners LLC Has $153.31 Million Stake in Medpace Holdings, Inc. $MEDP

Riverbridge Partners LLC trimmed its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 25.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 272,969 shares of the company’s stock after selling 92,119 shares during the period. Medpace accounts for 2.9% of Riverbridge Partners LLC’s portfolio, making the stock its 6th largest holding. Riverbridge Partners LLC owned approximately 0.97% of Medpace worth $153,313,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently bought and sold shares of MEDP. Fifth Third Wealth Advisors LLC boosted its holdings in shares of Medpace by 2.6% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock valued at $379,000 after purchasing an additional 19 shares during the last quarter. BOKF NA grew its position in shares of Medpace by 0.8% during the third quarter. BOKF NA now owns 2,542 shares of the company’s stock valued at $1,307,000 after purchasing an additional 20 shares in the last quarter. HighPoint Advisor Group LLC increased its holdings in shares of Medpace by 2.8% in the third quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock worth $416,000 after purchasing an additional 22 shares during the last quarter. Whittier Trust Co. of Nevada Inc. increased its holdings in shares of Medpace by 35.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock worth $55,000 after purchasing an additional 27 shares during the last quarter. Finally, M&T Bank Corp lifted its position in shares of Medpace by 3.4% in the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after buying an additional 31 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

MEDP has been the subject of a number of research reports. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and dropped their price target for the company from $462.00 to $419.00 in a research note on Wednesday, February 18th. Mizuho set a $582.00 price objective on Medpace in a research note on Wednesday, February 11th. Truist Financial decreased their price objective on Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. Leerink Partners lowered their target price on Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research report on Wednesday, February 11th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a report on Wednesday, January 28th. Five analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $486.67.

Insider Activity at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president owned 15,000 shares in the company, valued at approximately $6,829,500. The trade was a 67.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 20.30% of the company’s stock.

Medpace Trading Down 0.0%

Shares of NASDAQ:MEDP opened at $466.60 on Friday. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $628.92. The company has a 50-day moving average price of $497.26 and a 200 day moving average price of $537.33. The company has a market cap of $13.24 billion, a price-to-earnings ratio of 30.50, a PEG ratio of 2.24 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. During the same quarter last year, the business posted $3.67 earnings per share. The firm’s revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.